These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9696006

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
    Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM.
    Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A, Gulberg V, Sauter G, Waggershauser T, Reiser M, Gerbes AL.
    Hepatogastroenterology; 1998 Mar; 45(24):2315-21. PubMed ID: 9951915
    [Abstract] [Full Text] [Related]

  • 10. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E, Wengert A, Fleig WE.
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D, Trägner P, Wawer A, Porst H, Daniel WG, Gross P.
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [Abstract] [Full Text] [Related]

  • 14. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
    Møller S, Bendtsen F, Henriksen JH.
    Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500
    [Abstract] [Full Text] [Related]

  • 15. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T.
    Gut; 2000 Aug; 47(2):288-95. PubMed ID: 10896924
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.
    Rössle M, Gerbes AL.
    Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246
    [Abstract] [Full Text] [Related]

  • 20. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J.
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.